Julie E. Bauman, MD, MPH
To determine the recommended phase II schedule for the combination of MK-3475 (pembrolizumab) and standard, adjuvant cisplatin-radiotherapy in patients with high-risk, HPV-negative head and neck squamous cell carcinoma, based upon dose-limiting toxicity.
Patients with stage III-IVb, high-risk squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx; patients with oropharyngeal cancer must be p16-negative.
Activated November 28, 2016
Protocol Documents and Forms
- The protocol and related documents are available at NRG-HN003 (Enter CTEP IAM credentials to access NRG Oncology Member Login)